Next Entertainment World Co., Ltd. Secures Funds for Dividends and Share Buybacks… Enhancing Shareholder Value
Proposal to Reduce Capital Reserves to Be Tabled at Next Month’s Shareholders’ Meeting
Plan to Transfer Part of Capital Reserves to Retained Earnings
Continued Investment in Content… Laying the Groundwork for Shareholder Returns
[Edaily Reporter YUN GI BACK ] Content media group Next Entertainment World Co., Ltd.(160550)announced on the 20th that it will submit a proposal to reduce its capital reserve and transfer funds to retained earnings at an extraordinary general meeting of shareholders to be held on August 27. NEW logo. This proposal involves transferring a portion of the capital reserve to retained earnings within the limits permitted by the Commercial Act. The move is intended to secure funds for future shareholder return policies, such as the acquisition of treasury stock and dividends. Since this procedure involves only a reclassification of accounts within the capital section without changing total capital, it will not affect the company’s financial soundness. Next Entertainment World Co., Ltd.’s policy is to continuously strengthen content investment and business competitiveness while simultaneously implementing shareholder return policies over the medium to long term to enhance corporate value. A Next Entertainment World Co., Ltd. official stated, “The reduction of the capital reserve is a procedure to lay the groundwork for implementing shareholder return policies,” adding, “We will continue to review various measures to enhance shareholder value alongside strengthening our business competitiveness.” This proposal is scheduled to be finalized at the extraordinary general meeting of shareholders on August 27.
Current Status of Production Outsourcing by Major Home Appliance Manufacturers. (Graphic by Lee Mi-na, E-Daily)
Most global home appliance companies are devising survival strategies that rely on C…
“Wheee-ing, clang, wheee-ing, clang.”On the 7th, I visited the Lotte Mart Zeta Smart Center in Busan. As I opened the thick steel door and stepped into the frozen food storage area, the frigid air at …
Bae Yo-han, Head of Clinical Development at Kangstem Biotech, is presenting at a briefing on the results of the Phase 2a clinical trial for “OSCA,” held on the 29th at the FKI Tower in Yeouido, Seoul.…
